Self-crosslinked human serum albumin nanocarriers for systemic delivery of polymerized siRNA to tumors

• Published in: Biomaterials 2013-12, Vol.34 (37), p.9475-9485
• Main Authors: Son, Sohee, Song, Seungyong, Lee, So Jin, Min, Solki, Kim, Sun Ah, Yhee, Ji Young, Huh, Myung Sook, Chan Kwon, Ick, Jeong, Seo Young, Byun, Youngro, Kim, Sun Hwa, Kim, Kwangmeyung
• Format: Article
• Language: English
• Subjects: Advanced Basic Science; Animals; Cancer therapy; Cell Line, Tumor; Dentistry; Drug Carriers - chemistry; Human serum albumin; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Molecular; Neoplasms - blood supply; Neoplasms - genetics; Neoplasms - therapy; Neovascularization, Pathologic - genetics; Neovascularization, Pathologic - therapy; Polymerization; Polymerized siRNA; Protein based carrier; RNA Interference; RNA, Small Interfering - administration & dosage; RNA, Small Interfering - chemistry; RNA, Small Interfering - genetics; RNA, Small Interfering - therapeutic use; RNAi; Serum Albumin - chemistry; Sulfhydryl Compounds - chemistry; Vascular Endothelial Growth Factor A - genetics
• ISSN: 0142-9612; 1878-5905
• DOI: 10.1016/j.biomaterials.2013.08.085

Abstract The safe and effective systemic delivery of siRNA is a prerequisite for the successful development of siRNA-based cancer therapeutics. For the enhanced delivery of siRNA, cationic lipids and polymers have been widely used as siRNA carriers to form electrolyte complexes with anionic siRNA. However, the considerable toxicity of strong cationic-charged molecules hampers their clinical use. In this study, we utilized human serum albumin (HSA), which is the most abundant of the plasma proteins, as a siRNA carrier for systemic tumor-targeted siRNA delivery. Both HSA and siRNA molecules were thiol-introduced to improve the binding affinity for each other. The resulting thiolated HSA (tHSA) and polymerized siRNA (psi) formed stable nanosized complexes (psi–tHSAs) by chemical crosslinking and self-crosslinking. After internalization, the psi–tHSAs showed target gene silencing activity in vitro comparable to conventional Lipofectamine™-siRNA complexes, without remarkable cytotoxicity. After intravenous injection in tumor-bearing mice, psi–tHSAs accumulated specifically at the tumor sites, leading to efficient gene silencing in the tumors in a sequential manner. The therapeutic VEGF siRNA was loaded into psi–tHSAs, which significantly inhibited tumor-related angiogenesis in PC-3 tumor xenografts and resulted in retarding the growth of PC-3 tumors. The results showed that self-crosslinked psi–tHSA nanocarriers might provide a promising approach for the systemic siRNA therapy of various human cancers.